COMPASS Pathways Soars on Positive Psilocybin Trial Results

In a surprise move defying a broader market selloff, shares of COMPASS Pathways Plc (NASDAQ: CMPS) surged by 8.05% to $15.17 in pre-market trading today, following the announcement of positive results from its Phase 3 clinical trial for COMP360, a psilocybin-based therapy. This development has sparked significant interest and optimism among investors, marking a pivotal […]